Search clinical trials for: TST001

Total 255 results

Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Shanghai Zhongshan Hospital
Transcenta Holding Limited

Completed

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

China
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
HJB (Hangzhou) Co., Ltd.

Recruiting

TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Osteoporosis

China
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Colorectal Adenocarcinoma | Locally Advanced Solid Tumor | Metastatic Tumor

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Peking University

Recruiting

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Cancer

China
Strekin AG

Completed

Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL

Acute Hearing Loss

Switzerland, Czechia, Germany
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

Dry Eye Syndrome

Korea, Republic of
Third Harmonic Bio, Inc.

Terminated

A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Chronic Cold Urticaria

Netherlands, Germany
Blue Note Therapeutics
Durham VA Health Care System

Terminated

BNT001 Digital Therapeutic Feasibility Pilot Study

Cancer

United States
Livzon Pharmaceutical Group Inc.
Palm Beach CRO; Keystone Bioanalytical, Inc.

Completed

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Solid Tumor Refractory to Standard Therapy

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome (pSS)

Korea, Republic of
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Accendatech USA Inc.
Avance Clinical Pty Ltd.; C3 Research Associates

Recruiting

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme(GBM)

United States
Linda Van Eldik
Duke Clinical Research Institute; Alzheimer's Association

Completed

A MAD Study of TT301/MW189 in Healthy Volunteers

Healthy Adult Volunteers

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Histogen
United States Department of Defense

Terminated

Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage (hECM;HST003)

Cartilage Damage | Articular Cartilage Disorder of Knee | Microfractures

United States
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy

Korea, Republic of
CStone Pharmaceuticals

Completed

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Relapsed Small Cell Lung Cancer

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Respiratory Syncytial Virus Infections

China
Trinomab Biotech Co., Ltd.

Recruiting

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Respiratory Syncytial Virus Infections

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Sigma Tau Research Switzerland SA

Completed

SST0001 (Roneparstat) in Advanced Multiple Myeloma

Multiple Myeloma

Italy, Germany, Israel
Taizhou Hospital

Recruiting

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Esophageal Cancer | Chemotherapy | Immunotherapy | Radiation Therapy

China
University of Colorado, Boulder
TheraVasc Inc.

Completed

Sodium Nitrite to Treat Arterial Aging

Vascular Aging

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Shenzhen Turier Biotech Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 in Healthy Subjects

Healthy

China
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
Visirna Therapeutics HK Limited
Arrowhead Pharmaceuticals

Not yet recruiting

Study of VSA001 Injection in Chinese Healthy Adult Volunteers

Healthy Adult Volunteers

China

Search clinical trials for: TST001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations